endofocusFOCUS ЭндокринологияFOCUS. Endocrinology2713-01772713-0185ООО "Издательство "Перо"10.62751/2713-0177-2024-5-2-17endofocus-76Research ArticleСтатьиПатофизиологические аспекты влияния ожирения на течение вирусных заболеванийPathophysiological aspects of the effect of obesity on the course of viral diseaseshttps://orcid.org/0000-0002-3656-0312ЛобановаК. Г.LobanovaK. G.

Лобанова Кристина Геннадьевна –  к.м.н., ассистент кафедры эндокринологии лечебного факультета 

117997, Россия, г. Москва, ул. Островитянова, д. 1

Kristina G. Lobanova –  Can. Sci. (Med.), assistant of the department of endocrinology medical faculty

Moscow

miss.sapog@mail.ruhttps://orcid.org/0000-0002-6899-4457СкуридинаД. В.SkuridinaD. V.

Скуридина Дарья Викторовна –  ассистент кафедры эндокринологии лечебного факультета 

117997, Россия, г. Москва, ул. Островитянова, д. 1

Daria V. Skuridina – a ssistant of the department of endocrinology medical faculty

Moscow

shurpesha@mail.ruhttps://orcid.org/0000-0002-7675-4496БаироваВ. Э.BairovaV. E.

Баирова Валерия Эдуардовна –  студентка лечебного факультета

117997, Россия, г. Москва, ул. Островитянова, д. 1

Valeriya E. Bairova –  student of general medicine

Moscow

bairova.lera@mail.ruФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н. И. Пирогова» Минздрава РоссииPirogov Russian National Research Medical University2024130520245246–51Copyright © Лобанова К.Г., Скуридина Д.В., Баирова В.Э., 20242024Лобанова К.Г., Скуридина Д.В., Баирова В.Э.Lobanova K.G., Skuridina D.V., Bairova V.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://endofocus.elpub.ru/jour/article/view/76

COVID-19 представляет собой пандемию, создающую чрезвычайные проблемы в системе общественного здравоохранения во всем мире. В связи с этим продолжает активно проводиться поиск состояний, ассоциированных с тяжелым течением и увеличением уровня смертности от COVID-19. Ожирение создает неблагоприятный фон для течения COVID-19, увеличивая риск перевода пациентов в реанимационное отделение, потребность в искусственной вентиляции легких и значительно влияя на уровень смертности. В настоящем обзоре представлены данные о вероятных патогенетических механизмах влияния ожирения на течение COVID-19: рестриктивных нарушениях дыхательной системы, гиперактивации провоспалительного статуса, гиперкоагуляции, роли ренин-ангиотензин-альдостероновой системы (РААС) и аминокислоточувствительных путей. Прогрессивный рост новых случаев ожирения требуют дальнейшего изучения патогенетических механизмов влияния ожирения на течение COVID-19 и перспектив новых методов лечения данных пациентов.

COVID-19 is a pandemic causing extreme problems in the public health system around the world. In this regard, the search for conditions associated with severe course and an increase in the death rate from COVID-19 continues to be actively conducted. Obesity creates an unfavorable background for the course of COVID-19, increasing the risk of transferring patients to the intensive care unit, the need for artificial lung ventilation and significantly affecting the mortality rate. This review presents data on the probable pathogenetic mechanisms of the effect of obesity on the course of COVID-19: restrictive disorders of the respiratory system, hyperactivation of the proinflammatory status, hypercoagulation, the role of the renin-angiotensin-aldosterone system (RAAS) and amino acid-sensitive pathways. The progressive increase in new cases of obesity requires further study of the pathogenetic mechanisms of the effect of obesity on the course of COVID-19 and the prospects for new treatment methods for these patients.

ожирениеCOVID-19SARS-CoV-2ИМТизбыточная масса телавоспалениеObesityCovid-19SARS-CoV-2BMIoverweightinflammationReferencesДедов И. И., Шестакова М. В., Мельниченко Г. А., и др. Междисциплинарные клинические рекомендации «Лечение ожирения и коморбидных заболеваний» // Ожирение и метаболизм. – 2 021. – Т. 18. – № 1. – C. 5–99. doi: 10.14341/omet12714.Dedov I.I., Shestakova M.V., Melchenko G.A., et al. Interdisciplinary medical recommendations "Treatment of obesity and comorbid diseases"// Obesity and metabolism. — 2021. — Т. 18. — №1. — pp. 5-99. doi: 10.14341/omet12714.Michalakis K, Goulis DG, Vazaiou A, Mintziori G, Polymeris A, Abrahamian-Michalakis A. Obesity in the ageing man. Metabolism. 2013;62(10):1341–1349. doi:10.1016/j.metabol.2013.05.019Michalakis K, Goulis DG, Vazaiou A, Mintziori G, Polymeris A, Abrahamian-Michalakis A. Obesity in the ageing man. Metabolism. 2013;62(10):1341-1349. doi:10.1016/j.metabol.2013.05.019Huang H, Yan Z, Chen Y, Liu F. A social contagious model of the obesity epidemic. Sci Rep. 2016;6:37961. Published 2016 Nov 28. doi:10.1038/srep37961Huang H, Yan Z, Chen Y, Liu F. A social contagious model of the obesity epidemic. Sci Rep. 2016;6:37961. Published 2016 Nov 28. doi:10.1038/srep37961Bello-Chavolla OY, Bahena-López JP, Antonio-Villa NE, et al. Predicting Mortality Due to SARS-CoV-2: A Mechanistic Score Relating Obesity and Diabetes to COVID-19 Outcomes in Mexico. J Clin Endocrinol Metab. 2020;105(8): dgaa346. doi:10.1210/clinem/dgaa346Bello-Chavolla OY, Bahena-López JP, Antonio-Villa NE, et al. Predicting Mortality Due to SARS-CoV-2: A Mechanistic Score Relating Obesity and Diabetes to COVID-19 Outcomes in Mexico. J Clin Endocrinol Metab. 2020;105(8):dgaa346. doi:10.1210/clinem/dgaa346Goyal P, Choi JJ, Pinheiro LC, et al. Clinical Characteristics of Covid-19 in New York City. N Engl J Med. 2020 Jun 11;382(24):2372–2374. doi: 10.1056/NEJMc2010419.Goyal P, Choi JJ, Pinheiro LC, et al. Clinical Characteristics of Covid-19 in New York City. N Engl J Med. 2020 Jun 11;382(24):2372-2374. doi: 10.1056/NEJMc2010419.Peng YD, Meng K, Guan HQ, et al. Zhonghua Xin Xue Guan Bing Za Zhi. 2020;48(6):450–455. doi:10.3760/cma.j.cn112148-20200220-00105Peng YD, Meng K, Guan HQ, et al. Zhonghua Xin Xue Guan Bing Za Zhi. 2020;48(6):450-455. doi:10.3760/cma.j.cn112148-20200220-00105Nakeshbandi M, Maini R, Daniel P, et al. The impact of obesity on COVID-19 complications: a retrospective cohort study. Int J Obes (Lond). 2020 Sep;44(9):1832– 1837. doi: 10.1038/s41366-020-0648-x.Nakeshbandi M, Maini R, Daniel P, et al. The impact of obesity on COVID-19 complications: a retrospective cohort study. Int J Obes (Lond). 2020 Sep;44(9):1832-1837. doi: 10.1038/s41366-020-0648-x.Яшина Л. А. Избыточная масса тела, ожирение и патология легких: взгляд пульмонолога // Здоров'я Украïни. Квiтень, 2011. С. 14–15.Yashina L.A. Overweight, obesity and lung pathology: a pulmonologist's point of view// Healthy Ukraine, Kviten, 2011. pp. 14-15.Watson RA, Pride NB, Thomas EL, et al. Reduction of total lung capacity in obese men: comparison of total intrathoracic and gas volumes. J Appl Physiol (1985). 2010 Jun;108(6):1605–12. doi: 10.1152/japplphysiol.01267.2009.Watson RA, Pride NB, Thomas EL, et al. Reduction of total lung capacity in obese men: comparison of total intrathoracic and gas volumes. J Appl Physiol (1985). 2010 Jun;108(6):1605-12. doi: 10.1152/japplphysiol.01267.2009.SHARP JT, HENRY JP, SWEANY SK. THE TOTAL WORK OF BREATHING IN NORMAL AND OBESE MEN. J Clin Invest. 1964 Apr;43(4):728–39. doi: 10.1172/JCI104957.SHARP JT, HENRY JP, SWEANY SK. THE TOTAL WORK OF BREATHING IN NORMAL AND OBESE MEN. J Clin Invest. 1964 Apr;43(4):728-39. doi: 10.1172/JCI104957.Jones RL, Nzekwu MM. The effects of body mass index on lung volumes. Chest. 2006 Sep;130(3):827–33. doi: 10.1378/chest.130.3.827.Jones RL, Nzekwu MM. The effects of body mass index on lung volumes. Chest. 2006 Sep;130(3):827-33. doi: 10.1378/chest.130.3.827.Holley HS, Milic-Emili J, Becklake MR, et al. Regional distribution of pulmonary ventilation and perfusion in obesity. J Clin Invest. 1967 Apr;46(4):475–81. doi: 10.1172/JCI105549.Holley HS, Milic-Emili J, Becklake MR, et al. Regional distribution of pulmonary ventilation and perfusion in obesity. J Clin Invest. 1967 Apr;46(4):475-81. doi: 10.1172/JCI105549.Kress JP, Pohlman AS, Alverdy J, et al. The impact of morbid obesity on oxygen cost of breathing (VO(2RESP)) at rest. Am J Respir Crit Care Med. 1999 Sep;160(3):883–6. doi: 10.1164/ajrccm.160.3.9902058.Kress JP, Pohlman AS, Alverdy J, et al. The impact of morbid obesity on oxygen cost of breathing (VO(2RESP)) at rest. Am J Respir Crit Care Med. 1999 Sep;160(3):883-6. doi: 10.1164/ajrccm.160.3.9902058.Zavorsky GS, Murias JM, Kim DJ, et al. Waist-to-hip ratio is associated with pulmonary gas exchange in the morbidly obese. Chest. 2007 Feb;131(2):362–7. doi: 10.1378/chest.06-1513.Zavorsky GS, Murias JM, Kim DJ, et al. Waist-to-hip ratio is associated with pulmonary gas exchange in the morbidly obese. Chest. 2007 Feb;131(2):362-7. doi: 10.1378/chest.06-1513.Guilherme A, Virbasius JV, Puri V, et al. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 9: 367–377, 2008. doi:10.1038/nrm2391.Guilherme A, Virbasius JV, Puri V, et al. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 9: 367–377, 2008. doi:10.1038/nrm2391.Wang C, Ha X, Li W, et al. Correlation of TLR4 and KLF7 in Inflammation Induced by Obesity. Inflammation. 2017 Feb;40(1):42–51. doi: 10.1007/s10753-016-0450-z.Wang C, Ha X, Li W, et al. Correlation of TLR4 and KLF7 in Inflammation Induced by Obesity. Inflammation. 2017 Feb;40(1):42-51. doi: 10.1007/s10753-016-0450-z.Dhanraj P, Pitere R, Pepper MS. The impact of obesity on the cellular and molecular pathophysiology of COVID-19. S Afr Med J. 2020;0(0):13184. Published 2020 Dec 14.Dhanraj P, Pitere R, Pepper MS. The impact of obesity on the cellular and molecular pathophysiology of COVID-19. S Afr Med J. 2020;0(0):13184. Published 2020 Dec 14.Otsuka, R., Seino, Ki. Macrophage activation syndrome and COVID-19. Inflamm Regener 40, 19 (2020). doi: 10.1186/s41232-020-00131-w.Otsuka, R., Seino, Ki. Macrophage activation syndrome and COVID-19. Inflamm Regener 40, 19 (2020). doi: 10.1186/s41232-020-00131-w.Coperchini F, Chiovato L, Croce L, et al. The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Rev. 2020 Jun;53:25–32. doi: 10.1016/j.cytogfr.2020.05.003.Coperchini F, Chiovato L, Croce L, et al. The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Rev. 2020 Jun;53:25-32. doi: 10.1016/j.cytogfr.2020.05.003.Tanaka T, Narazaki M, Kishimoto T, et al. Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy. 2016 Jul;8(8):959–70. doi: 10.2217/imt-2016-0020.Tanaka T, Narazaki M, Kishimoto T, et al. Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy. 2016 Jul;8(8):959-70. doi: 10.2217/imt-2016-0020.Sindhu S, Thomas R, Shihab P, et al. Obesity Is a Positive Modulator of IL-6R and IL-6 Expression in the Subcutaneous Adipose Tissue: Significance for Metabolic Inflammation. PLoS One. 2015 Jul 22;10(7): e0133494. doi: 10.1371/journal.pone.0133494.Sindhu S, Thomas R, Shihab P, et al. Obesity Is a Positive Modulator of IL-6R and IL-6 Expression in the Subcutaneous Adipose Tissue: Significance for Metabolic Inflammation. PLoS One. 2015 Jul 22;10(7):e0133494. doi: 10.1371/journal.pone.0133494.Stone JH, Frigault MJ, Serling-Boyd NJ, et al. BACC Bay Tocilizumab Trial Investigators. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. N Engl J Med. 2020 Dec 10;383(24):2333–2344. doi: 10.1056/NEJMoa2028836.Stone JH, Frigault MJ, Serling-Boyd NJ, et al. BACC Bay Tocilizumab Trial Investigators. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. N Engl J Med. 2020 Dec 10;383(24):2333-2344. doi: 10.1056/NEJMoa2028836.Moiseev S, Avdeev S, Tao E, et al. Efficacy of tocilizumab in the intensive care unit patients with COVID-19: a retrospective cohort study. Klini ches kaya farmakologiya i terapiya = Clin Pharmacol Ther 2020;29(4):17–25 (In Russ.). DOI 10.32756/0869–5490–2020–4–17–25.Moiseev S, Avdeev S, Tao E, et al. Efficacy of tocilizumab in the intensive care unit patients with COVID-19: a retrospective cohort study. Klini ches kaya farmakologiya i terapiya = Clin Pharmacol Ther 2020;29(4):17-25 (In Russ.). DOI 10.32756/ 0869-5490-2020-4-17-25.Al-Baadani A, Eltayeb N, Alsufyani E, et al. Efficacy of tocilizumab in patients with severe COVID-19: Survival and clinical outcomes. J Infect Public Health. 2021 Aug;14(8):1021–1027. doi: 10.1016/j.jiph.2021.05.015.Al-Baadani A, Eltayeb N, Alsufyani E, et al. Efficacy of tocilizumab in patients with severe COVID-19: Survival and clinical outcomes. J Infect Public Health. 2021 Aug;14(8):1021-1027. doi: 10.1016/j.jiph.2021.05.015.Беспалова И.Д.. Лептин как индуктор воспаления и окислительного стресса при метаболическом синдроме // Бюллетень сибирской медицины. 2014;13(1):20–26. https://doi.org/10.20538/1682–0363–2014–1–20–26.Bespalovа I.D. Leptin as an inducer of inflammation and oxidative stress by metabolic syndrome Bulletin // of Siberian Medicine. 2014;13(1):20-26. (In Russ.) https://doi.org/10.20538/1682-0363-2014-1-20-26De Rosa V, Procaccini C, Calì G, et al. A key role of leptin in the control of regulatory T cell proliferation. Immunity. 2007 Feb;26(2):241–55. doi: 10.1016/j.immuni.2007.01.011.De Rosa V, Procaccini C, Calì G, et al. A key role of leptin in the control of regulatory T cell proliferation. Immunity. 2007 Feb;26(2):241-55. doi: 10.1016/j.immuni.2007.01.011.Zhang AJ, To KK, Li C, et al. Leptin mediates the pathogenesis of severe 2009 pandemic influenza A(H1N1) infection associated with cytokine dysregulation in mice with diet-induced obesity. J Infect Dis. 2013 Apr 15;207(8):1270–80. doi: 10.1093/infdis/jit031.Zhang AJ, To KK, Li C, et al. Leptin mediates the pathogenesis of severe 2009 pandemic influenza A(H1N1) infection associated with cytokine dysregulation in mice with diet-induced obesity. J Infect Dis. 2013 Apr 15;207(8):1270-80. doi: 10.1093/infdis/jit031.Кузник Б. И. Цитокины и система гемостаза II. Цитокины и коагуляционный гемостаз / Б. И. Кузник // Тромбоз, гемостаз и реология. – 2 012. – № 3(51). – С. 9–29.Kuznik B.I. Cytokines and hemostasis II. Cytokines and coagulation hemostasis/ B.I. Kuznik //Thrombosis, hemostasis and rheology.-2012. – № 3(51). – pp. 9-29.]Campello E, Zabeo E, Radu CM, et al. Hypercoagulability in overweight and obese subjects who are asymptomatic for thrombotic events. Thromb Haemost. 2015 Jan;113(1):85–96. doi: 10.1160/TH14-02-0156.Campello E, Zabeo E, Radu CM, et al. Hypercoagulability in overweight and obese subjects who are asymptomatic for thrombotic events. Thromb Haemost. 2015 Jan;113(1):85-96. doi: 10.1160/TH14-02-0156.Dragon-Durey M-A, Chen X, Kirilovsky A, et al. (2021) Differential association between inflammatory cytokines and multiorgan dysfunction in COVID-19 patients with obesity. PLoS ONE 16(5): e0252026. Doi:10.1371/journal.pone.0252026.Dragon-Durey M-A, Chen X, Kirilovsky A, et al. (2021) Differential association between inflammatory cytokines and multiorgan dysfunction in COVID-19 patients with obesity. PLoS ONE 16(5): e0252026. Doi:10.1371/journal.pone.0252026.Викулова О. К., Зураева З. Т., Никанкина Л. В., Шестакова М. В. Роль ренинангиотензиновой системы и ангиотензинпревращающего фермента 2 типа в развитии и течении вирусной инфекции СОVID-19 у пациентов с сахарным диабетом. Сахарный диабет. 2020;23(3):242–249. doi:10.14341/DM12501.Vikulova O.K., Zuraeva Z., Nikankina L.V., et al. The role of renin-angiotensin system and angiotensin-converting enzyme 2 (ACE2) in the development and course of viral infection COVID-19 in patients with diabetes mellitus. Diabetes mellitus. 2020;23(3):242-249. (In Russ.) doi:10.14341/DM12501Peci S, et al. “The Role of Soluble Recombinant ACE2 in SARS-COV-2 Patients”. EC Pulmonology and Respiratory Medicine 9.7 (2020): 17–22Peci S, et al. “The Role of Soluble Recombinant ACE2 in SARS-COV-2 Patients”. EC Pulmonology and Respiratory Medicine 9.7 (2020): 17-22Xiao L, Sakagami H, Miwa N, et al. ACE2: The key Molecule for Understanding the Pathophysiology of Severe and Critical Conditions of COVID-19: Demon or Angel? Viruses. 2020 Apr 28;12(5):491. doi: 10.3390/v12050491.Xiao L, Sakagami H, Miwa N, et al. ACE2: The key Molecule for Understanding the Pathophysiology of Severe and Critical Conditions of COVID-19: Demon or Angel? Viruses. 2020 Apr 28;12(5):491. doi: 10.3390/v12050491.Hamming I, Timens W, Bulthuis ML, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004 Jun;203(2):631–7. doi: 10.1002/path.1570.Hamming I, Timens W, Bulthuis ML, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004 Jun;203(2):631-7. doi: 10.1002/path.1570.Iannelli A, Favre G, Frey S, et al. Obesity and COVID-19: ACE 2, the Missing Tile. Obes Surg. 2020 Nov;30(11):4615–4617. doi: 10.1007/s11695-020-04734-7.Iannelli A, Favre G, Frey S, et al. Obesity and COVID-19: ACE 2, the Missing Tile. Obes Surg. 2020 Nov;30(11):4615-4617. doi: 10.1007/s11695-020-04734-7.Akoumianakis I, Filippatos T. The renin-angiotensin-aldosterone system as a link between obesity and coronavirus disease 2019 severity. Obes Rev. 2020 Sep;21(9): e13077. doi: 10.1111/obr.13077.Akoumianakis I, Filippatos T. The renin-angiotensin-aldosterone system as a link between obesity and coronavirus disease 2019 severity. Obes Rev. 2020 Sep;21(9):e13077. doi: 10.1111/obr.13077.Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020 Mar;63(3):364–374. doi: 10.1007/s11427-020-1643-8.Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020 Mar;63(3):364-374. doi: 10.1007/s11427-020-1643-8.Braude P, Carter B, Short R, et al. The influence of ACE inhibitors and ARBs on hospital length of stay and survival in people with COVID-19. Int J Cardiol Heart Vasc. 2020 Dec; 31:100660. doi: 10.1016/j.ijcha.2020.100660.Braude P, Carter B, Short R, et al. The influence of ACE inhibitors and ARBs on hospital length of stay and survival in people with COVID-19. Int J Cardiol Heart Vasc. 2020 Dec;31:100660. doi: 10.1016/j.ijcha.2020.100660.Takashina C, Tsujino I, Watanabe T, et al. Associations among the plasma amino acid profile, obesity, and glucose metabolism in Japanese adults with normal glucose tolerance. Nutr Metab (Lond). 2016 Jan 19; 13:5. doi: 10.1186/s12986015-0059-5.Takashina C, Tsujino I, Watanabe T, et al. Associations among the plasma amino acid profile, obesity, and glucose metabolism in Japanese adults with normal glucose tolerance. Nutr Metab (Lond). 2016 Jan 19;13:5. doi: 10.1186/s12986-015-0059-5.Okekunle AP, Li Y, Liu L, et al. Abnormal circulating amino acid profiles in multiple metabolic disorders. Diabetes Res Clin Pract. 2017 Oct;132:45–58. doi: 10.1016/j.diabres.2017.07.023.Okekunle AP, Li Y, Liu L, et al. Abnormal circulating amino acid profiles in multiple metabolic disorders. Diabetes Res Clin Pract. 2017 Oct;132:45-58. doi: 10.1016/j.diabres.2017.07.023.Lushchak O, Strilbytska OM, Yurkevych I, et al. Implications of amino acid sensing and dietary protein to the aging process. Exp Gerontol. 2019 Jan;115:69–78. doi: 10.1016/j.exger.2018.11.021.Lushchak O, Strilbytska OM, Yurkevych I, et al. Implications of amino acid sensing and dietary protein to the aging process. Exp Gerontol. 2019 Jan;115:69-78. doi: 10.1016/j.exger.2018.11.021.Philips AM, Khan N. Amino acidsensing pathway: A major check point in the pathogenesis ofobesity and COVID-19. Obesity Reviews. 2021;22: e13221. doi:10.1111/obr.132218of8.Philips AM, Khan N. Amino acidsensing pathway: A major check point in the pathogenesis ofobesity and COVID-19. Obesity Reviews. 2021;22:e13221. doi:10.1111/obr.132218of8.Berlanga JJ, Ventoso I, Harding HP, et al. Antiviral effect of the mammalian translation initiation factor 2alpha kinase GCN2 against RNA viruses. EMBO J. 2006 Apr 19;25(8):1730–40. doi: 10.1038/sj.emboj.7601073.Berlanga JJ, Ventoso I, Harding HP, et al. Antiviral effect of the mammalian translation initiation factor 2alpha kinase GCN2 against RNA viruses. EMBO J. 2006 Apr 19;25(8):1730-40. doi: 10.1038/sj.emboj.7601073.

The authors declare that there are no conflicts of interest present.